Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)

Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Earnings & Valuation

This table compares Vor Biopharma and Liminatus Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	($386.83)	-0.02
Liminatus Pharma	N/A	N/A	N/A	($0.12)	-8.67

Liminatus Pharma is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vor Biopharma and Liminatus Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Liminatus Pharma	N/A	N/A	N/A

Insider and Institutional Ownership

97.3% of Vor Biopharma shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vor Biopharma and Liminatus Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1	5	4	1	2.45
Liminatus Pharma	1	0	0	0	1.00

Vor Biopharma currently has a consensus price target of $73.17, indicating a potential upside of 777.40%. Given Vor Biopharma’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Liminatus Pharma.

Summary

Vor Biopharma beats Liminatus Pharma on 7 of the 8 factors compared between the two stocks.

About Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company’s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.